Trial Profile
A retrospective study to evaluate consolidation therapy comprising of bortezomib, thalidomide, and dexamethasone in Japanese patients with multiple myeloma, who had undergone autologous stem cell transplantation therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Dec 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2015 New trial record